Navigation Links
Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Date:8/28/2007

- Plan Extends Financial Resources Beyond 2008 -

SOUTH SAN FRANCISCO, Calif., Aug. 28 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it is reducing its workforce by approximately 25 percent, and implementing a revised operating plan that focuses its efforts on generating definitive data from its lead programs while streamlining the company's operations and extending its financial resources beyond 2008.

Based on a rigorous assessment of its product portfolio, Sunesis' top priority is the advancement of its lead product candidate, SNS-595, for the treatment of acute myeloid leukemia (AML). Having seen clinical activity and a favorable therapeutic profile in its ongoing Phase 1 single-agent clinical trial of SNS-595, Sunesis is working closely with its clinical and regulatory advisors to design a registration trial for the treatment of elderly AML patients which it plans to initiate by the end of 2008. Additionally, Sunesis will soon begin dosing patients in a Phase 1b clinical trial of relapsed AML patients, combining SNS-595 with cytarabine, the leading treatment standard.

In addition to its development activities in AML, over the next eighteen months Sunesis expects to continue to advance its ongoing studies of SNS-595 in ovarian cancer, SNS-032 in B-cell malignancies and SNS-314 in solid tumors.

Positive data from any of these studies could support registration strategies or one or more significant development-stage collaborations. Sunesis' refocused research team will continue to generate insights on the chemistry and biology of the company's product candidates that may inform and guide clinical trials, to advance novel, small molecule i
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Speaker announces business members of IT Task Force
4. Doyle announces technology tax credits for Berbee
5. Doyle announces new energy, global warming policies
6. Doyle announces $80M renewable energy strategy
7. GE announces first installation of Discovery VCT
8. UWM announces winners of RGI awards
9. Third Wave announces two senior management appointments
10. Mirus announces new method for making antibodies
11. Merge announces sofware updates, upcoming acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 30, 2015 Ascendis Pharma A/S (Nasdaq: ... its innovative TransCon technology to address significant unmet ... a six-month Phase 2 study to evaluate the ... in 53 treatment-naïve, pre-pubertal children with growth hormone ... pleased with the top-line results from our Phase ...
(Date:7/30/2015)... ... ... its 2015 growth plan and as a follow up to the recently announced expansion of ... pleased to announce that it has begun construction on a new Microbiological Laboratory. The new ... dedicated to basic USP 51, USP 61, and USP 62 testing specific to raw materials. ...
(Date:7/29/2015)... Sanofi, un leader mondial ... pour le premier semestre 2015. Le Directeur Général ... Visionner l,interview vidéo et lire la transcription ... Au sommaire de l,interview :  - ... - Diabète - Praluent ...
(Date:7/29/2015)... (Q2 2015: +14% CER / 20% of sales) led the regional performance in ... , as well as solid contributions from Korea, India ... Middle East / Africa (Q2 2015: ... , Turkey and the United Kingdom ... excluding U.S. HPV sales, on demand across all customer classes. The top seven ...
Breaking Biology Technology:Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7Whitehouse Labs Formally Announces Plans to Open a Microbiological Laboratory 2QIAGEN Reports Results for Second Quarter and First Half of 2015 2QIAGEN Reports Results for Second Quarter and First Half of 2015 3QIAGEN Reports Results for Second Quarter and First Half of 2015 4QIAGEN Reports Results for Second Quarter and First Half of 2015 5QIAGEN Reports Results for Second Quarter and First Half of 2015 6QIAGEN Reports Results for Second Quarter and First Half of 2015 7QIAGEN Reports Results for Second Quarter and First Half of 2015 8QIAGEN Reports Results for Second Quarter and First Half of 2015 9QIAGEN Reports Results for Second Quarter and First Half of 2015 10
... , ... (DIA) and the US Food and Drug Administration (USFDA) will host Assessing Benefits and Risks ... , ... 2009 -- The Drug Information Association (DIA) and the US Food and Drug ...
... ... Products announced a financial support partnership with several key vendors to ... collective effort with a dedicated "Pink" section on their website, ... will be available. Spectrum will also donate $1 per order ...
... Inc. (OTC Bulletin Board: BTEL) announced results for the fiscal ... or $0.33 per diluted share, on revenues of $12,640,000. ... diluted share on revenues of $11,495,000 in fiscal year 2008. ... of $174,000 or $0.06 per diluted share, on revenues of ...
Cached Biology Technology:Global Regulators to Discuss Benefit-Risk Approaches of Medicinal Products at DIA Workshop 2Global Regulators to Discuss Benefit-Risk Approaches of Medicinal Products at DIA Workshop 3Spectrum Announces Support Partnership for Breast Cancer Research During Breast Cancer Awareness Month 2Spectrum Announces Support Partnership for Breast Cancer Research During Breast Cancer Awareness Month 3Biotel Announces Fourth Quarter and Year End Results 2
(Date:7/9/2015)... 2015 Research and ... the "Biometrics for Banking; Market & Technology ... to their offering. The adoption for ... growth and the forecast is that by 2020 ... companies involved in delivering biometric systems to the ...
(Date:7/8/2015)... NEW YORK , July 8, 2015 /PRNewswire/ ... today announced BD & Guidepoint Mentor, a ... access to Guidepoint,s expert network services. ... cutting-edge technologies to improve healthcare delivery and outcomes and, ... each start-up entrepreneur will be able to directly engage ...
(Date:7/7/2015)... 2015  Based on its recent analysis of ... Credence ID, LLC with the 2015 Asia-Pacific ... Year Award. Credence ID has developed a low-cost, ... of offering enrollment and identification solutions to the ... was formed by experts from the mobile biometrics ...
Breaking Biology News(10 mins):Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5
... start-ups Straw Fuels and AdFerTech have won prizes ... supported by the EU,s main climate innovation initiative, ... the Climate-KIC Early Stage Entrepreneurs Prize, which will ... of Climate-KIC,s pan-European start-up Acceleration Programme. Straw Fuels, ...
... Colo., USA GSA Bulletin postings ... as seen in the Pyrenees; facies architecture in ... Permian Maroon Formation; preglacial fluvial gorges and valleys; ... Africa; Ediacaran fossils from Mistaken Point, Newfoundland; geologic ...
... Increasing block-rate water budgets are an innovative type of ... sizes are based on household characteristics, environmental conditions, and ... what constitutes "efficient" water use given those characteristics and ... relatively low for the most essential uses of water ...
Cached Biology News:Liquor converter, BBQ logs win €20K prizes at UK innovation showcase 2Mistaken point, Sanctuary of Zeus, catastrophic outburst floods, shocked sand grains 2Mistaken point, Sanctuary of Zeus, catastrophic outburst floods, shocked sand grains 3Mistaken point, Sanctuary of Zeus, catastrophic outburst floods, shocked sand grains 4Mistaken point, Sanctuary of Zeus, catastrophic outburst floods, shocked sand grains 5Mistaken point, Sanctuary of Zeus, catastrophic outburst floods, shocked sand grains 6Mistaken point, Sanctuary of Zeus, catastrophic outburst floods, shocked sand grains 7Mistaken point, Sanctuary of Zeus, catastrophic outburst floods, shocked sand grains 8Mistaken point, Sanctuary of Zeus, catastrophic outburst floods, shocked sand grains 9Mistaken point, Sanctuary of Zeus, catastrophic outburst floods, shocked sand grains 10An innovative approach to promote water use efficiency 2An innovative approach to promote water use efficiency 3
... Exiqon's miRCURY LNA technology enables sensitive and ... blotting. miRCURY LNA Detection probes have high ... and sensitive detection of miRNAs. Due to ... LNA probes less than 1/10 the amount ...
Rabbit polyclonal to Vitronectin ( Abpromise for all tested applications). Antigen: Full length Vitronectin protein (Mouse). Entrez Gene ID: 7448 Swiss Protein ID: P04004...
... [PRMT5-21] to PRMT5 Arginine methylation is ... only recently been linked to protein activity. ... have been identified in mammalian cells. These ... regulatory functions by methylation of key proteins ...
... Kit uses a simplified procedure and streamlines ... The kit is based on the three ... and sodium bisulfite where cytosine is converted ... innovative in-column desulphonation reaction eliminates several precipitation ...
Biology Products: